Earnings Summary

Kiniksa Pharmaceuticals Ltd’s revenue jumped 719.64% since last year same period to $99.14Mn in the Q3 2022. On a quarterly growth basis, Kiniksa Pharmaceuticals Ltd has generated 267.55% jump in its revenue since last 3-months.

Kiniksa Pharmaceuticals Ltd’s net profit jumped 833.67% since last year same period to $224.09Mn in the Q3 2022. On a quarterly growth basis, Kiniksa Pharmaceuticals Ltd has generated 1221.53% jump in its net profits since last 3-months.

Kiniksa Pharmaceuticals Ltd’s net profit margin jumped 189.51% since last year same period to 226.05% in the Q3 2022. On a quarterly growth basis, Kiniksa Pharmaceuticals Ltd has generated 405.14% jump in its net profit margins since last 3-months.

Kiniksa Pharmaceuticals Ltd’s earning per share (EPS) estimates for the current quarter stand at -0.22 - a -128.21% fall from last quarter’s estimates.

Kiniksa Pharmaceuticals Ltd’s earning per share (EPS) estimates for the current year stand at -0.22.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Kiniksa Pharmaceuticals Ltd’s return on assets (ROA) stands at 0.02.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Kiniksa Pharmaceuticals Ltd’s return on equity (ROE) stands at 0.63.